# A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)

Source: https://onco.cc/trials/nct07742215/  
OnCo record `nct07742215` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Daratumumab, Dexamethasone and Pomalidomide in multiple myeloma, run by Biocad, now recruiting.

## Summary

A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) is a phase 3 interventional study registered as NCT07742215 by Biocad, with 390 participants planned, started 2026-06-15 and due to reach its primary completion in 2028-07. Interventions recorded: BCD-248 + daratumumab and Daratumumab + pomalidomide + dexamethasone.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07742215
- Phase: 3
- Setting: A Phase III Open-Label, Randomized Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab Versus Daratumumab, Pomalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Sponsor: Biocad
- Enrolled: 390

## Sources

- ClinicalTrials.gov NCT07742215: https://clinicaltrials.gov/study/NCT07742215

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/)
- companies: [Biocad](https://onco.cc/companies/biocad/)

---
JSON: https://onco.cc/api/v1/entities/nct07742215.json